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Abstract
Introduction: Data supporting external validity of trial results allows clinicians to assess the applicability of a
study’s findings to their practice population. Socio-economic status (SES) of trial participants may be critical to
external validity given the relationship between social and economic circumstances and health. We explored how
this is documented in reports of RCTs in four major general medical journals.
Methods: The contents lists of four leading general medical journals were hand searched to identify 25
consecutive papers reporting RCT results in each journal (n = 100). Data on demographic characteristics were
extracted from each paper’s Table 1 only (or equivalent).
Results: Authors infrequently reported key demographic characteristics relating to SES of RCT participants. Age and
gender of participants were commonly reported. Less than 10% reported occupational group, employment status,
income or area based measures of disadvantage.
Conclusions: Without adequate reporting of key indicators of SES in trial participants it is unclear if lower SES
groups are under-represented. If such groups are systematically under-recruited into trials, this may limit the
external validity and applicability of study findings to these groups. This is in spite of the higher health-care need
in more disadvantaged populations. Under-representation of low SES groups could underestimate the reported
effect of an intervention for those with a higher baseline risk. The marginal benefit identified in a trial with poor or
no representation of lower SES participants could significantly underestimate the potential benefit to a low SES
community. More transparency in this reporting and greater attention to the impact of SES on intervention
outcomes in clinical trials is needed. This could be considered in the next revision of the CONSORT statement.
Introduction
The CONSORT statement [1] encourages authors
reporting randomised controlled trial (RCT) results to
include “baseline demographic and clinical characteris-
tics for each group” of participants. This baseline infor-
mation should be presented in a table, effectively
becoming the “Table 1” in published reports of RCTs.
Demographic, from “demography”, refers to character-
istics related to the “life-conditions of communities of
people” [2]. Significantly, the CONSORT statement is
not prescriptive as to which demographic features
should be reported, giving no indication as to which are
important or useful to readers.
CONSORT notes that one reason for reporting this
data is to assess comparability of study groups. Study
groups “should be compared at baseline for important
demographic and clinical characteristics so that readers
can assess how comparable the groups were”.
Another reason for reporting of baseline demographic
characteristics is for assessment of external validity of
trial results. This is of relevance to clinicians who must
assess the applicability of study findings to their practice
populations and to individual patients particularly in pri-
mary care dealing with communities and people with
multiple conditions and vulnerabilities [3]. For example,
age and sex of trial participants is of obvious relevance
to external validity of a trial. A good illustration of this
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elderly in trials of interventions in ischaemic heart dis-
ease which makes applicability of their results to those
patient groups less certain [4].
Another critical demographic characteristic of study
populations that may impact upon assessment of exter-
nal validity is socio-economic status (SES). SES of a
s t u d yp a r t i c i p a n tm a yb ei n f e r r e df r o mi n d i v i d u a lc h a r -
acteristics such as employment status, occupation, edu-
cational achievement or place of residence (where an
area based measure of socioeconomic disadvantage is
available such as the Socio-Economic Indexes for Areas,
Index of Relative Socio-Economic Disadvantage (SEIFA
IRSD) in Australia for example [5]). There is now over-
whelming evidence of the relationship between social
and economic circumstances and health and inequities
in health [6]. There are many ways that SES may affect
the external validity of a trial’s results. For example, if
an intervention is trialled in a population of high SES
patients, co-morbidity is likely to be less than in lower
SES groups: how applicable these results would then be
to a disadvantaged population where co-morbidity is a
key consideration is unclear. Similarly, theoretically an
educational intervention that requires a high level of lit-
eracy trialled in a relatively well-educated study popula-
t i o nm a yb el e s sa p p l i c a b l et oap r a c t i c ep o p u l a t i o n
where education and literacy levels are lower. While re-
analysis of observational studies on hormone replace-
ment therapy in postmenopausal women revealed the
p i v o t a lr o l eo fS E Sa sac o n f o u n d e r[ 7 ] ,s u b - a n a l y s e s
from interventional studies are uncommon.
The aim of this paper is to identify the extent to
which demographic attributes, in particular the SES
characteristics, of trial participants are documented in
the reporting of randomised controlled trials in four
major general medical journals.
Methods
The contents lists of four leading international general
medical journals, the New England Journal of Medicine,
the Journal of the American Medical Association, the
Lancet and the British Medical Journal, were hand
searched to identify papers reporting RCT results.
Working backwards in time from February 1
st 2010, 25
consecutive papers reporting RCT results were identified
in each of the four journals (N = 100).
Inclusion criteria for papers were: reporting a rando-
mised controlled trial; a clinical trial in human subjects;
data collection and analysis at the level of the individual
participant; phase 3 or 4 trials; and reporting of a single
trial. As the focus of this analysis was on generalizability
we included published RCTs covering a wide range of
conditions, populations and interventions.
Data on the reporting of demographic characteristics
were extracted from each paper’s Table 1 (or equiva-
lent). Data extraction was limited to data on characteris-
tics of patients included in the studies as appearing in
tabular form and as available to readers, as this is the
CONSORT recommendation. The sampling frame or
methods of each trial were not the focus of this analysis.
The choice of most relevant demographic factors to be
included was made by author consensus. Included for
data extraction were: age, sex, marital status, ethnicity,
language use, geographic or area-based measures (eg
rural/urban location, area measure of disadvantage, dis-
tance from the trial centre), employment status, occupa-
tional status, income, and educational attainment. In
studies with children we assessed reported data for chil-
dren as well as parents. If any of the variables for either
of the groups was mentioned in the table they were clas-
sified as “reported”. We also extracted data on whether
other demographic markers of life conditions were
reported including weight/BMI, smoking and alcohol
use. We regarded gender as reported if a trial was gen-
der specific. A data extraction form was constructed
which included dichotomous responses for each of the
identified demographic factors (reported/not reported).
Each of the four authors extracted data from two jour-
nals (BMJ/Lancet or NEJM/JAMA) resulting in two
independent assessments of whether demographic data
were reported in each paper. Differences in assessment
of data from individual papers were resolved by
consensus.
Results are presented as percentage of eligible papers
reporting each of the demographic features of their
study populations.
Results
Results are presented in the Table 1, which shows the
percentage of papers reporting each included socio-
demographic variable. Twelve papers reported on RCTs
in gender specific populations and nine in children and
infants.
Discussion
We found that reports of RCTs poorly documented key
demographic characteristics relating to SES. Almost all
trials reported age and gender of participants. Ethnicity
and education level were the next most commonly
reported variables. Very few trials reported occupational
group, employment status, income or area based mea-
sures of disadvantage.
The relevance of any one or more demographic char-
acteristics to the internal and external validity of any
individual trial will vary depending on the intervention
being trialled. Nevertheless, while CONSORT is not
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should be reported, the intent of the statement is to
“facilitate clarity, completeness, and transparency of
reporting” noting that “explicit descriptions, not ambi-
guity or omission, best serve the interests of all readers”.
It seems unlikely that the proportions of papers found
to be reporting detailed baseline characteristics in this
study are consistent with this stated intent. Clinicians,
particularly primary care clinicians, seeking to determine
the applicability of trial results to their patients may not
be provided with sufficient data to do so.
Of particular note is our finding of the relative lack of
reporting of SES of trial participants. This makes it
impossible to assess whether low SES groups are ade-
quately represented in trial populations. As noted ear-
lier, there is a range of ways that SES may be important
to assessing a trials external validity. It has been sug-
gested that lower SES groups may be under-represented
in trials [8,9] but without adequate reporting of this key
characteristic this is unclear.
There are good reasons why people from more disad-
vantaged circumstances may be under-represented in
trials. These groups have difficulties in accessing health
care so may also be likely to have difficulty with “acces-
sing” trials. For example, complying with private trans-
port or communication technology requirements of
study protocols may be a barrier. Lower levels of literacy
or speaking a language other than that used in study
documents may tend to exclude people from some
trials. Co-morbidity, more common in more disadvan-
taged populations [10] is also likely to lead to exclusion
from trials with strict inclusion criteria. If subjects from
lower SES background are systematically under-
recruited into trials, the external validity of study
findings to these groups may be limited. Higher health-
care need in more disadvantaged populations is well
documented. Lower SES patients have higher prevalence
of disease, more multi-morbidity, more psychological
co-morbidity and illness has a greater impact on their
lives [10]. In addition to the recognised “inverse care
law” [11], our results identify a potential “inverse evi-
dence law” which implies limitations in generalisability
of trial findings for lower SES groups.
An intervention that has an effect in a trial may have
little effect in people of low socio-economic status for
many reasons, for example, they may receive many
drugs already and they may have low compliance with
medicine or whatever treatment has been investigated.
They may also be so ill because of co-morbid diseases
that the effect would not have been reproduced among
them, if a trial had been undertaken which included
adequate representation from such groups.
The opposite possibility is equally important. If the
under-reporting of SES does in fact reflect under-repre-
sentation of low SES groups, this may also mean that
the effect of an intervention could be underestimated
for the very group for whom it is likely to offer the
greatest benefit. An intervention might be found to have
a marginally significant effect in an RCT with an under-
representation of lower SES subjects, where trial partici-
pants have an overall lower burden of disease. The mar-
ginal benefit identified in such an unrepresentative trial
could significantly underestimate the potential benefit to
a community starting with higher need and higher base-
line risk.
I nt h i ss t u d yw ei l l u s t r a t eh ow SES characteristics are
reported. There may be many reasons for study authors
not to report this in Table 1 even though they have
Table 1 Reporting of demographic variables in 100 RCTs published in four leading general medicine journals
Demographic variable Percentage of papers reporting that
variable
Age 99
Sex 99
Weight/BMI 39
Ethnicity 37
Smoking 24
Educational attainment 23
Marital Status 13
Any area-based measure (eg index of deprivation or disadvantage, rurality distance from health
centres etc)
10
Employment status 10
Alcohol 4
Occupational status 2
Income 2
Language spoken 0
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is designed to assist systematic assessment of generaliz-
ability of results. Time-poor clinicians therefore might
rely on Table 1 to assess the relevance of the study find-
ings to their patients.
While our analysis is based on a convenience sample
of medical journals reporting RCTs, the papers were
drawn from leading general medical journals and if any-
thing we would expect this to lead to a bias towards
more complete reporting. Future studies should examine
the reporting of sampling frames and could focus parti-
cularly on trials in areas where socio-economic back-
ground is known to have an impact on the outcome.
Conclusions
Reporting of socio-economic characteristics of clinical
trial participants is limited. This reduces our ability to
assess the generalisability of study findings to day-to-day
clinical practice, particularly in primary care. Moreover,
if hidden behind this lack of reporting is a systematic
exclusion of lower SES participants from clinical trials,
this might underestimate potential health gains, and in
absence of this information we might be dismissing
interventions that could benefit disadvantaged popula-
tions and help to reduce health inequity. More transpar-
ency in this reporting and greater attention to the
impact of SES on intervention outcomes in clinical trials
is needed. It may be important for the next revision of
the CONSORT statement to consider explicit reporting
of relevant SES as one of its criteria.
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